MBEVMED@EC2703A

Everbright Bioscience Announces Progress of Its mRNA Cancer Vaccine at AACR Annual Meeting

Ever Sea Medicines (Singapore) Pte. Ltd., a wholly-owned subsidiary of CanSino, Acquires 100% of the Issued Share Capital and Related Assets of HASTEN BIOPHARMACEUTICALS (SG) PTE. LTD.

Innubeay 2025 Announces Full Year Revenue of 1.707 billion Yuan and Publishes Annual Report

EVEREST MED released FY2025 9 Months Earnings on March 25, 2026 (BJT), with actual revenue of HKD 1.172 B and EPS of HKD -0.9092

EVEREST MED released FY2025 Q3 earnings on March 25 (BJT), actual revenue HKD 689 M, actual EPS HKD -0.0781

EVEREST MED released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 700.89 M, actual EPS HKD -0.0776

EVEREST MED released FY2025 Annual Earnings on March 25 After-Market (BJT), actual revenue HKD 1.865 B (forecast HKD 1.873 B), actual EPS HKD -0.9727 (forecast HKD -0.5476)

Etripamil Nasal Spray Rights Acquired by LuViz for Greater China

CanSino Biologics (Singapore) to be Acquired by Everest Medicines

EVEREST MED to Release FY2025 Annual Earnings on March 26 After-Market (BJT), Forecast Revenue HKD 1.921 B, EPS HKD -0.5617

Everbright Bio Obtains NMPA Approval for New Drug VELSIPITY® for Ulcerative Colitis

Cloudtop Echos Receives Exclusive Commercialization Authorization for MT1013 in China and Asia Pacific

Merck & Moderna Disclose mRNA Cancer Vaccine Five-Year Clinical Data

Wu Yifang Increases Holdings in CanSino Biologics by 30,000 Shares

Chairman Wu Yifang of CanSino Biologics Purchased 30,000 Shares

CanSino Biologics Shares Plunge Over 20% After Generic Drug Approval

CloverDX Receives FDA Approval and License from Lib Therapeutics

Everbright Neon Announces 2030 Development Strategy

Top Directors and Major Shareholders of CanSino Biologics Increase Their Shares

Everbright BioTech Signs Commercialization and Licensing Agreement with Haisen Biopharma

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

01952

BOCOM International Holdings Company analyst maintained a Buy rating on Everest Medicines Ltd. yesterday and set a price target of HK$84.00. The company’s shares closed yesterday at HK$39.56.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Everest Medicines Ltd. with a HK$69.50 average price target.

Tip Ranks

EVEREST MED

BOCOM INTL

BOCOM International Holdings Company Reaffirms Their Buy Rating on Everest Medicines Ltd. (1952)

512290

159316

516820

588860

516500

520880

159849

159102

159570

520690

159615

159892

159506

159567

512010

159837

EverSea Medicines, a subsidiary of Everest Medicines, has signed a share purchase agreement to acquire Hasten Biopharmaceuticals for $250 million. The deal includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in the Asia Pacific region. The acquisition aims to enhance Everest Medicines' market presence and commercial capabilities. Hasten Biopharmaceuticals reported normalized revenue of $82.23 million and EBITDA of $27.27 million in December 2025. The acquisition is expected to expedite product commercialization and support international growth.

Pharmaceutical Technology

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

EverSea Medicines to acquire Hasten Biopharmaceuticals

In a report released yesterday, from CICC maintained a Buy rating on Everest Medicines Ltd., with a price target of HK$55.00.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Everest Medicines Ltd. is a Moderate Buy with an average price target of HK$55.00.

CICC Remains a Buy on Everest Medicines Ltd. (1952)

Everest Medicines Limited reported a significant revenue increase to CNY 1,706.68 million for 2025, up from CNY 706.68 million the previous year, while narrowing its net loss to CNY 297.77 million from CNY 1,041.38 million. This improvement suggests enhanced operational efficiency and may positively influence investor sentiment regarding the company's path to profitability. However, risks remain due to reliance on key products and potential reimbursement challenges. Analysts project future revenues of CN¥3.7 billion by 2029, indicating a fair value of HK$56.76, suggesting a 49% upside from current prices.

Simplywall

Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?

36Kr learned that the Hong Kong innovative pharmaceutical company EVEREST MED disclosed its full-year performance report for 2025. The data shows that the company achieved total revenue of 1.707 billion yuan in 2025, a significant increase of 142%; it turned a profit under Non-IFRS standards, earning 187 million yuan, and achieved positive operating cash flow in the fourth quarter. As of December 31, 2025, the company had ample cash reserves of 2.731 billion yuan, strongly supporting commercialization expansion, independent research and development, and medium to long-term strategic layout

36Kr

EVEREST MED: Performance is expected to grow significantly by 142% in 2025, achieving a turnaround to profitability

EVEREST MED announced its full-year results for the year ended December last year, with a revenue of RMB 1.707 billion, an increase of 141.5% year-on-year. The loss narrowed to RMB 298 million, compared to a loss of RMB 1.041 billion in the same period last year; the loss per share was RMB 0.89. No dividend was declared

AASTOCKS

In the performance report, EVEREST MED's annual loss narrowed to 298 million RMB, and no dividend will be distributed

Everest Medicines Ltd. has published its audited annual results for the year ending December 31, 2025. The full report is available in Chinese and English, with printed copies to be sent to shareholders by April 2026. The results were reviewed by Ernst & Young and comply with Hong Kong listing rules. The current analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$36.00. The company focuses on developing innovative biopharmaceuticals and has a market cap of HK$12.47B.

Everest Medicines Publishes Audited 2025 Annual Results and Report

Everest Medicines (SEHK:1952) has experienced a significant share price decline of 4.0% in one day and 32.6% over the past three months. Despite a strong three-year total shareholder return of approximately 2.2x, the stock is currently trading at HK$33.02, which is 62% below intrinsic estimates and 72% below analyst targets. The fair value is estimated at HK$91.47, indicating it is undervalued. However, risks remain if key products underperform or if pricing pressures in China increase. Investors are encouraged to assess the underlying data and consider potential opportunities in the healthcare sector.

A Look At Everest Medicines (SEHK:1952) Valuation After Recent Share Price Pullback

Everest Medicines Ltd. has signed a letter of intent to potentially acquire Hasten Biopharmaceuticals (SG) Pte. Ltd., which holds rights to 14 chronic disease products in the Asia-Pacific region. The company will pay a refundable RMB200 million deposit and gain six months of exclusivity for negotiations. This move aims to expand Everest's chronic disease portfolio. The current analyst rating for Everest Medicines (HK:1952) is a Hold with a price target of HK$36.00.

Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition

MBEVMED@EC2703A(28767.HK)

BOCOM International Holdings Company Reaffirms Their Buy Rating on Everest Medicines Ltd. (1952)

EverSea Medicines to acquire Hasten Biopharmaceuticals

CICC Remains a Buy on Everest Medicines Ltd. (1952)

Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?

EVEREST MED: Performance is expected to grow significantly by 142% in 2025, achieving a turnaround to profitability